Thumbnail image of

Twenty-five years have passed since the Japanese Society of Neuroimmunology was established. During these years the membership has grown to 584 people, and the society continues to issue its own journal in English. The memorandum of intent dated 6 August 1988 states the aim of the society as follows (translated from the original Japanese):

Rapid progress in the fields of neuroscience and immunology has revealed a close relationship between the nervous system and the immune system. Accordingly, the two fields have become integrated, and a new research area, neuroimmunology, has arisen. Prospects for multifaceted research into and treatments for intractable neuroimmunological diseases, such as multiple sclerosis (MS), HTLV-1-associated myelopathy (HAM), Guillain–Barré syndrome (GBS), myasthenia gravis (MG), polymyositis and paraneoplastic neurologic syndrome, have thus improved. Obviously, this discipline has a strong interdisciplinary nature, and cooperation and free exchange of opinions among experts in various positions are critically important. Creating the proper occasion for discussions and presentations of interdisciplinary research has been our urgent task. In view of these circumstances, we propose to set up the Japanese Society of Neuroimmunology as a new organization.

In other words, this society was created to provide an occasion for interdisciplinary research presentations and free exchange of ideas on immune-mediated neurological diseases; that is, in the new academic field of neuroimmunology. We aim to succeed those great minds that established this society, and take a leap forward into a new age.

I believe that the true identity of the Japanese Society of Neuroimmunology lies in those areas of neuroimmunology focused on brain, nerve and muscle diseases. The members of this society target various neuroimmunological diseases. Furthermore, it has become clear in recent years that neurodegenerative disorders have a strong relationship with immune-related mechanisms. Therefore, this society also targets the immunological aspects of neurodegenerative diseases; for example, the neuroglial inflammation in amyotrophic lateral sclerosis and Alzheimer's disease. In terms of basic science, neuroscience and immune science related to brain, nerve and muscle are included. In terms of clinical science, breakthroughs on disease pathomechanisms and the development of novel immune therapies targeting not only neuroimmunological diseases, but also neurodegenerative disease, are covered. In this way, this society targets wide research areas with neuroimmunological science at the core. Thus, the aim of this society is to facilitate the development of new immunological treatments for intractable neuroimmunological and neurodegenerative diseases, based on the elucidation of the mechanisms underlying such diseases, and to bring to patients the most appropriate remedy.

As the publication of this society, Clinical and Experimental Neuroimmunology offers the opportunity to present interdisciplinary research spanning a wide range of areas, from basic to clinical. I think this journal has assumed a role in dispatching important information as the sole journal targeting neuroimmunology-related research in Asia. For the past 3 years, it has been published in three annual issues as issues 1–3. The role for this journal has become larger in light of the rapid progress in the area of neuroimmunology. Therefore, I have decided to enhance the editing system following my recent appointment as President of this society. This is done in an attempt to remain current with the rapid progress in neuroimmunology. To achieve this, I expect that the review and publication processes of this journal will be promoted, and the presence of the journal within the neuroimmunology research field will be escalated. I welcome submissions not only from our membership, but also from non-members around the world. The enhancement of the editing system will enable us to provide more polite review comments and more rapid review. With such strengths and a wider acceptance of submissions, better communication of important information in the field is expected. Our emerging role is to present cutting-edge information as an international opinion leader in the field of neuroimmunology. We will work hard toward the fruition of these goals together with the new Chief Editors. We all look forward to receiving submissions.